Treating Older Patients With Myeloma: Is Frailty More Important Than Age?
In this peer-to-peer discussion two experts discuss the nuances and challenges of treating elderly patients with myeloma, and why therapies need to be tailored based on frailty status rather than age.
In this peer-to-peer discussion, Angela Dispenzieri, MD, of the Mayo Clinic in Rochester, Minnesota, and Ashley Rosko, MD, PhD, of the Ohio State University in Columbus, talk about the nuances and challenges of treating elderly patients with cancer, and why therapies need to be tailored based on frailty status rather than age.
At the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2–6 in Chicago, Dispenzieri and Rosko spoke at an education session on treating older multiple myeloma patients that also included Sergio Giralt, MD, of Memorial Sloan Kettering Cancer Center in New York, and Maria-Victoria Mateos, MD, PhD, of the University of Salamanca Hospital in Spain.
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
![We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fd5a069c33bbfe917bc7c0b1bb13d76c0a815cc44-234x234.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.")
